Signal active
Investment Firm
Overview
Psilos has established itself as a successful healthcare investor and has demonstrated its ability to effectively identify and analyze attractive investment opportunities, to structure and consummate high-quality transactions and to work with entrepreneurial management teams from company inception to successful liquidity events. They understand entrepreneurial drive and the importance of developing relationships with companies that reinforce management's creative energies. Psilos seeks investments where they can have a significant positive impact on the strategic development of their portfolio companies, leveraging their broad network of relationships with both strategic and financial investors, corporate partners, investment banks, and industry leaders across the healthcare field. Psilos invests in businesses that are poised to establish enduring market value by developing fundamental improvements in the healthcare system as a whole. Psilos seeks to be the lead investor in companies that have: • An industry-transforming service, technology or product idea; • A strong, experienced and visionary management team; • Broad applicability to a large and growing market; • A compelling and sound business model with superior returns potential; • Strong intellectual property and high barriers to entry; and, • Entrepreneurs desirous of forming a strong partnership with their investors
Highlights
1998
Venture Capital
1-10
37
18
16
Late Stage Venture, Early Stage Venture
Micro Vc
Location
New York, New York, United States, North America
Contact Information
Social
Profile Resume
Psilos Group, established in 1998 and headquartered in New York, New York, United States, North America., specializes in Late Stage Venture, Early Stage Venture investments across Health Care, Medical Device, Robotics, Information Technology, Financial Services, Venture Capital, Finance, Infrastructure, Banking, Biotechnology. The organization boasts a portfolio of 37 investments, with an average round size of $18.5M and 16 successful exits. Their recent investments include OmniGuide, 3i Group, AngioScore, Pelion Venture Partners, QuestMark Partners. The highest investment round they participated in was $45.8B. Among their most notable exits are OmniGuide and 3i Group. Explore their portfolio in detail, see who is connected to them, and find their contact information on our platform.
Investment portfolio
37
1
18
16
Investments
37
Annouced Date | Organization Name | Industry | Money Raised |
---|---|---|---|
Jul 16, 2013 | Gamma Medica | Biotechnology | 16.0M |
Sep 24, 2013 | PatientSafe Solutions | Software | 7.0M |
Oct 22, 2014 | Gamma Medica | Biotechnology | 5.0M |
Sep 25, 2017 | PatientSafe Solutions | Software | 25.0M |
Exits
16
Funding Timeline
37
0
2
Funding Rounds
37
Psilos Group has raised 37 rounds. Their latest funding was raised on Sep 25, 2017 from a Venture Round - PatientSafe Solutions round.
Annouced Date | Transaction Name | Number of Investors | Money Raised | Lead Investor |
---|---|---|---|---|
Jul 16, 2013 | Series A - Gamma Medica | - | 16.0M | - |
Sep 24, 2013 | Series C - PatientSafe Solutions | - | 7.0M | - |
Oct 22, 2014 | Series B - Gamma Medica | - | 5.0M | - |
Sep 25, 2017 | Venture Round - PatientSafe Solutions | - | 25.0M | - |
Investors
0
There is no funding round available on this profile
Fund raised
2
Susa Ventures has raised a total of $590M across 6 funds, their latest being Susa Ventures Opportunities II. This fund was announced on Aug 30, 2021 and raised a total of $250M.
Annouced Date | Fund Name | Money Raised |
---|---|---|
May 10, 2013 | OTPPLESS | 1.0M |
May 11, 2013 | OTPPLESS | 1.0M |
Invest in industries
Recent Activity
There is no recent news or activity for this profile.